Risk adjusted net present value: What is the current valuation of Enliven Therapeutics’s ELVN-002?

ORLANDO — Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis

As­cle­tis’ sub­sidiary Gan­nex re­vealed that its non-al­co­holic steato­hep­ati­tis (NASH) drug can­di­date sig­nif­i­cant­ly re­duced av­er­age lev­els of liv­er fat in pa­tients en­rolled in a mid-stage tri­al,